Rare Variant in Metallothionein 1E Increases the Risk of Type 2 Diabetes in a Chinese Population
© 2023 by the American Diabetes Association..
OBJECTIVE: To uncover novel targets for the treatment of type 2 diabetes (T2D) by investigating rare variants with large effects in monogenic forms of the disease.
RESEARCH DESIGN AND METHODS: We performed whole-exome sequencing in a family with diabetes. We validated the identified gene using Sanger sequencing in additional families and diabetes- and community-based cohorts. Wild-type and variant gene transgenic mouse models were used to study the gene function.
RESULTS: Our analysis revealed a rare variant of the metallothionein 1E (MT1E) gene, p.C36Y, in a three-generation family with diabetes. This risk allele was associated with T2D or prediabetes in a community-based cohort. MT1E p.C36 carriers had higher HbA1c levels and greater BMI than those carrying the wild-type allele. Mice with forced expression of MT1E p.C36Y demonstrated increased weight gain, elevated postchallenge serum glucose and liver enzyme levels, and hepatic steatosis, similar to the phenotypes observed in human carriers of MT1E p.C36Y. In contrast, mice with forced expression of MT1E p.C36C displayed reduced weight and lower serum glucose and serum triglyceride levels. Forced expression of wild-type and variant MT1E demonstrated differential expression of genes related to lipid metabolism.
CONCLUSIONS: Our results suggest that MT1E could be a promising target for drug development, because forced expression of MT1E p.C36C stabilized glucose metabolism and reduced body weight, whereas MT1E p.C36Y expression had the opposite effect. These findings highlight the importance of considering the impact of rare variants in the development of new T2D treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Diabetes care - 46(2023), 12 vom: 01. Dez., Seite 2249-2257 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zou, Xiantong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9038-94-2 |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2337/dc22-2031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363707530 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363707530 | ||
| 003 | DE-627 | ||
| 005 | 20240114232003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc22-2031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM363707530 | ||
| 035 | |a (NLM)37878528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zou, Xiantong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rare Variant in Metallothionein 1E Increases the Risk of Type 2 Diabetes in a Chinese Population |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: To uncover novel targets for the treatment of type 2 diabetes (T2D) by investigating rare variants with large effects in monogenic forms of the disease | ||
| 520 | |a RESEARCH DESIGN AND METHODS: We performed whole-exome sequencing in a family with diabetes. We validated the identified gene using Sanger sequencing in additional families and diabetes- and community-based cohorts. Wild-type and variant gene transgenic mouse models were used to study the gene function | ||
| 520 | |a RESULTS: Our analysis revealed a rare variant of the metallothionein 1E (MT1E) gene, p.C36Y, in a three-generation family with diabetes. This risk allele was associated with T2D or prediabetes in a community-based cohort. MT1E p.C36 carriers had higher HbA1c levels and greater BMI than those carrying the wild-type allele. Mice with forced expression of MT1E p.C36Y demonstrated increased weight gain, elevated postchallenge serum glucose and liver enzyme levels, and hepatic steatosis, similar to the phenotypes observed in human carriers of MT1E p.C36Y. In contrast, mice with forced expression of MT1E p.C36C displayed reduced weight and lower serum glucose and serum triglyceride levels. Forced expression of wild-type and variant MT1E demonstrated differential expression of genes related to lipid metabolism | ||
| 520 | |a CONCLUSIONS: Our results suggest that MT1E could be a promising target for drug development, because forced expression of MT1E p.C36C stabilized glucose metabolism and reduced body weight, whereas MT1E p.C36Y expression had the opposite effect. These findings highlight the importance of considering the impact of rare variants in the development of new T2D treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Metallothionein |2 NLM | |
| 650 | 7 | |a 9038-94-2 |2 NLM | |
| 650 | 7 | |a MT1E protein, human |2 NLM | |
| 700 | 1 | |a Hu, Mengdie |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiuting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Lingli |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Meng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xueying |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yingying |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yufeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xianghai |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yuanping |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Xueyao |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Linong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 46(2023), 12 vom: 01. Dez., Seite 2249-2257 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:2249-2257 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc22-2031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2023 |e 12 |b 01 |c 12 |h 2249-2257 | ||